Robert Pollack, MD has been certified in the Restrictive Program called Spravato REMS (Risk Evaluation and Mitigation Strategy) for the administration and monitoring of Spravato, the newly released Intranasal formulation of Esketamine for the treatment of TRD (Treatment Resistant Depression). Janssen announced that they received FDA approval for this medication February 5 , 2019.

For more information about Spravato please see our blog post.